Y-Intercept (HK)’s Celldex Therapeutics CLDX Stock Holding History

Y-Intercept (HK)’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.2M	Sell	32,257 -12,935	-29%	-$418K	0.02%	964
2026 Q1	$1.43M	Buy	+45,192	New	+$1.23M	0.03%	883
2025 Q4	–	Sell	-48,906	Closed	-$1.27M	–	1601
2025 Q3	$1.27M	Sell	48,906 -9,492	-16%	-$220K	0.03%	861
2025 Q2	$1.19M	Buy	+58,398	New	+$1.14M	0.03%	856
2024 Q4	–	Sell	-30,538	Closed	-$1.04M	–	1246
2024 Q3	$1.04M	Buy	30,538 +3,146	+11%	+$120K	0.06%	435
2024 Q2	$1.01M	Buy	+27,392	New	+$1.03M	0.06%	487

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Y-Intercept (HK)'s CLDX Position: Q2 2026 in Review

Y-Intercept (HK) reduced its Celldex Therapeutics (CLDX) stake by 29% in Q2 2026, selling an estimated $418K and leaving 32,257 shares worth $1.2M. The position accounts for 0.02% of the portfolio, ranked #964.

Y-Intercept (HK) first reported a position in CLDX in Q2 2024 and has held it in 6 quarters since. The position peaked at $1.43M in Q1 2026. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Y-Intercept (HK) held 32,257 shares of Celldex Therapeutics worth $1.2M as of Q2 2026.
Y-Intercept (HK) sold 12,935 Celldex Therapeutics shares in Q2 2026, an estimated $418K.
Celldex Therapeutics made up 0.02% of Y-Intercept (HK)'s portfolio in Q2 2026, its #964 holding.
Y-Intercept (HK) first reported a position in Celldex Therapeutics in Q2 2024 and has held it in 6 quarters since.
Y-Intercept (HK)'s Celldex Therapeutics position peaked at $1.43M in Q1 2026.
254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.